Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 138.7% | -24.2% | 11.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.3% | 96% | 96.5% | 96.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -185.4% | -468.6% | -689.9% | -438.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -129.8% | -446.7% | -595.5% | -342.4% |
| EPS Diluted | -0.42 | -0.84 | -1.2 | -1.56 |
| % Growth | 50% | 30% | 23.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |